Neurologic AEs on Rise as Checkpoint Inhibitors Evolve Neurologic AEs on Rise as Checkpoint Inhibitors Evolve

Potentially lethal immune-related adverse events (AEs) are expected to increase as anti-PD-1 therapies for solid tumors expand to include other cancers.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news